Basic Serc Information

• INN (International Nonproprietary Name): Betahistine
• Brand Names Available In Canada (English): Serc; ACT Betahistine
• ATC Code: N07CA01; Classification: Other nervous system drugs; antivertigo agent
• Forms & Dosages: Tablet; Strengths 8 mg, 16 mg, 24 mg; Oral route; Common packaging includes blister packs and boxes
• Manufacturers In Canada (English): BGP PHARMA ULC (Teva, ACT Betahistine)
• Registration Status In Canada (English): Approved for prescription; notable Health Canada DINs include 02243878 (16 mg) and 02247998 (24 mg)
• OTC / Rx Classification: Prescription-only (Rx) in Canada and most markets

Availability & Price Landscape

Where can Canadians find Serc or betahistine and what can they expect to pay?

Major national pharmacy chains such as Shoppers Drug Mart, Rexall and London Drugs commonly dispense betahistine on prescription and may stock 16 mg or 24 mg strengths in larger stores.

Smaller stores and rural locations often need to order stock for same-day or next-day pickup, and availability varies by province and by individual store size.

Online pharmacy searches in Canada typically return the branded options Serc or ACT Betahistine or generics that reference betahistine tablets.

Provincial rules influence online fulfilment; some provinces require a local prescriber for dispensing and others limit inter‑provincial shipping for prescription products.

Expect price variation by package size (30–100 tablet packs) and strength, with lower per‑tablet cost for larger packs.

Provincial drug plans such as Ontario Drug Benefit, BC PharmaCare and RAMQ rarely list betahistine as a standard benefit, so coverage tends to be case‑by‑case or through exceptional access.

Cross‑border purchasing from U.S. vendors is common among Canadians but carries regulatory, customs and safety trade‑offs and may result in non‑DIN products being seized or lacking Canadian post‑market oversight.

Major National Pharmacy Chains (Shoppers Drug Mart, Rexall, London Drugs)

Large retail chains can often order Serc or ACT Betahistine for same‑day or next‑day pickup when the item is not on the shelf.

In-store pharmacists can confirm DINs 02243878 and 02247998 on packaging and advise about dosing and interactions.

Pricing at chains varies by province and by promotional pricing; larger package sizes usually reduce the per‑tablet cost.

Online Pharmacy Trends In Canada (Including Provincial Restrictions)

Canadian online pharmacies return branded or generic betahistine listings and require a valid prescription for fulfilment.

Some provinces limit dispensing to pharmacies licensed in the same province, and others ask for a local prescriber to authorise online orders.

Shipping rules can add 2–5 business days within the same province and longer for interprovincial deliveries depending on pharmacy policy.

Price Ranges By Package Size (With Provincial Differences)

Typical package sizes range from 30 to 100 tablets and come in 16 mg and 24 mg strengths.

Smaller packs cost more per tablet, while 60–100 tablet packs usually have the lowest per‑tablet price.

Provincial formularies rarely cover betahistine routinely, so many Canadians use private insurance, exceptional access programs, or pay out of pocket.

Canadian Patient Insights & Satisfaction Levels

What are Canadians saying online about Serc and betahistine?

Discussion is common on Reddit Canada, HealthBoards, AskDocs and local Facebook support groups, where patients exchange practical experience and tips.

Many users report reduced vertigo frequency after several weeks of betahistine, especially for Ménière’s flares, while others describe limited or no benefit.

Commonly reported positive outcomes include fewer spinning attacks, improved tolerance for daily activities and decreased tinnitus flare intensity for some patients.

Challenges raised by patients are stomach upset, inconsistent symptom control, and delays getting prescriptions or accessing the drug across provinces.

Patients often combine betahistine with vestibular rehabilitation and lifestyle changes such as a low‑sodium diet or prescribed diuretics.

Brand switching (Serc versus ACT Betahistine) is frequently discussed, with most patients reporting similar effects when dosage and adherence are consistent.

Cost is a recurring theme; many Canadians check provincial drug plans or use private insurance to help offset out‑of‑pocket costs.

Forum And Review Platforms (Reddit Canada, HealthBoards, AskDocs)

Forums tend to present mixed‑effect anecdotes rather than controlled trial data, which is helpful for setting practical expectations but not for estimating population effectiveness.

Typical thread topics include onset time, side effects, brand comparisons and tips for combining betahistine with vestibular therapy.

Reported Benefits And Challenges From Canadian Patients

Benefit highlights from community reports include a steady reduction in attack frequency over weeks and better day‑to‑day functioning.

Common complaints include gastrointestinal upset and disappointment when vertigo persists or only partially improves.

Patients advise tracking symptoms with a diary to help prescribers decide on continuation, dose adjustment or referral to ENT specialists.

Product Overview & Brand Variants

Which brands and strengths of betahistine are available in Canada?

The International Nonproprietary Name (INN) is betahistine and the common brand in Canada is Serc, with ACT Betahistine listed as a manufacturer option.

Available tablet strengths in Canada align with 16 mg and 24 mg formulations, matching the DINs registered for the market.

Packaging is typically film‑coated tablets in blister packs or boxes, and common pack sizes vary by retailer.

The ATC classification is N07CA01 and the drug is categorised as an antivertigo agent.

INN And Brand Names Used In Canada

Use the INN "betahistine" on clinical pages and show the brand names Serc and ACT Betahistine on product listings.

Ensure product images show the DIN and strength clearly, as DINs 02243878 (16 mg) and 02247998 (24 mg) reassure customers of Health Canada registration.

Legal Classification Under Health Canada

Betahistine is classified as a prescription‑only medicine in Canada and must be dispensed with a valid prescription.

Listings and packaging should display the relevant DIN and the Rx classification so customers understand legal requirements.

Indications In Local Canadian Medical Practice

When do Canadian clinicians typically prescribe betahistine?

Health Canada–registered betahistine products are most commonly prescribed for symptoms of vertigo and for Ménière’s disease flare control.

Clinicians usually initiate betahistine for recurrent episodic vertigo suspected to be linked to endolymphatic hydrops or Ménière’s disease.

Product pages should mirror the approved indication in the DIN‑linked monograph and direct clinicians to the full product monograph for detail.

Approved Uses (Health Canada DIN Context)

Approved indications align with symptomatic control of vertigo and Ménière’s disease as stated in Health Canada registrations.

Pharmacists should check the DIN and monograph to ensure counseling matches the marketed indication for the specific product on hand.

Off‑Label Patterns In Canadian Healthcare

Some clinicians prescribe betahistine off‑label as an adjunct for chronic dizzy syndromes, vestibular migraine or persistent vestibulopathy after specialist consultation.

Typical treatment courses run for weeks to months, with reassessment at 4–8 weeks to judge response and tolerability.

How It Works In The Body

What does betahistine do to reduce vertigo?

In plain language: betahistine helps improve blood flow and signalling in the inner ear so balance structures can stabilise and patients can experience fewer spinning sensations over time.

It does not stop an attack instantly but may reduce the frequency and intensity of attacks when taken regularly.

Layman’s Explanation (Canadian Patient‑Friendly Tone)

Think of betahistine as a medicine that helps the ear’s circulation and nerve signalling reset gradually, reducing pressure in the balance organ and calming troublesome vertigo.

Most people notice improvement over several weeks rather than immediately after a single dose.

Clinical Detail From Health Canada Resources

Pharmacologically, betahistine acts as an H1 receptor agonist and H3 receptor antagonist, increasing histaminergic activity in vestibular nuclei and improving labyrinthine blood flow.

Health Canada monographs classify it under ATC N07CA01 as an antivertigo agent and describe a gradual onset of measurable benefit over weeks.

Dosage & Administration

How should Serc be taken for best effect?

Standard regimens commonly start with 16 mg two to three times daily or 24 mg twice daily, with a usual maximum of 48 mg per day.

Treatment for Ménière’s disease or chronic vertigo is often continued for weeks to months and adjusted to symptom control and tolerability.

Standard Regimens Per Canadian Guidelines

A typical starting regimen is 16 mg two to three times a day, or 24 mg twice a day, depending on prescriber preference and patient response.

Advise taking with food if stomach upset occurs, and maintain adherence for several weeks to evaluate benefit.

Adjustments By Patient Type (With Canadian Clinical Notes)

Children: not generally recommended due to limited safety and efficacy data.

Elderly: no routine dose reduction required, but monitor comorbidities, renal and hepatic function and potential polypharmacy interactions.

Renal or hepatic impairment: start cautiously and monitor clinical response; specific dose adjustments are not routinely defined.

Missed dose guidance: take the missed dose when remembered unless it is near the next scheduled dose; do not double up.

Overdose signs include nausea, vomiting and, in very large doses, convulsions; seek emergency care if overdose is suspected.

Contraindications & Side Effects

Who should avoid betahistine and what adverse effects should patients expect?

Absolute contraindications include known hypersensitivity to betahistine or excipients and pheochromocytoma because of hypertensive crisis risk.

Pregnancy is generally a contraindication or not recommended, and patients should discuss risks and alternatives with their prescriber.

Common (Health Canada‑Approved List)

Common side effects are gastrointestinal upset such as nausea or dyspepsia, headache, mild drowsiness and allergic skin reactions like rash or pruritus.

Advise patients to take the medicine with food if they experience stomach upset and to report persistent adverse effects to their prescriber.

Rare But Serious (With Canadian Pharmacovigilance Data)

Rare but serious reactions reported include severe allergic reactions and hypertensive crises when used in patients with pheochromocytoma; immediate medical attention is required in these cases.

Encourage reporting of suspected adverse reactions to Canada Vigilance to support post‑market safety monitoring.

Comparable Medicines In Canada

What other medications are used for vertigo and how do they compare to betahistine?

Common alternatives include dimenhydrinate (e.g., Gravol formulations), meclizine (various brands) and, in some countries, cinnarizine though the latter is less commonly used in Canada.

Dimenhydrinate is effective for acute nausea and vertigo but is sedating.

Meclizine is a longer‑acting vestibular suppressant that may also cause drowsiness.

Betahistine tends to be used for long‑term reduction in attack frequency and is generally less sedating, but the evidence base is mixed.

Alternatives Table (With DIN References)

When preparing a product comparison, list medication name, mechanism, Rx/OTC status in Canada and common uses, and cross‑check DINs or NPNs as available.

Pros And Cons List

Betahistine pros: potential for long‑term reduction in vertigo frequency and fewer sedative effects.

Betahistine cons: prescription required, mixed evidence quality and potential GI side effects.

Dimenhydrinate pros: rapid relief for acute nausea; cons: sedation and shorter duration of action for long‑term control.

Meclizine pros: longer symptom control for acute attacks; cons: drowsiness and limited effect on long‑term attack frequency.

Current Research & Trends

What does recent evidence say about betahistine effectiveness and safety?

Systematic reviews and meta‑analyses up to the mid‑2020s report mixed‑quality evidence, with some trials showing modest reductions in vertigo attack frequency and others limited by methodology.

Recent studies from 2022–2025 have focused on pragmatic trial designs, comparisons with vestibular rehabilitation and real‑world observational cohorts exploring long‑term effectiveness and safety.

Canadian‑specific RCTs are limited, so clinicians often rely on international evidence and registry data to guide practice.

Product pages should summarise the evidence level as low to moderate and emphasise that benefit may be individual, directing clinicians to full reviews or the Health Canada monograph for detail.

Common Patient Questions In Canada

• Do I need a prescription? Yes, betahistine is prescription‑only in Canada and product pages should display the DIN and Rx status.
• How long until it works? Many patients report gradual improvement over weeks; discuss a trial period with your prescriber and reassess at 4–8 weeks.
• Is it covered by provincial drug plans? Coverage varies; ODB, PharmaCare and RAMQ rarely list it routinely and exceptional access may be required.
• Can I drive while taking it? Betahistine is not strongly sedating for most people, but monitor for dizziness or drowsiness before driving.
• Is it safe in pregnancy or breastfeeding? It is often not recommended; consult obstetric care and review risks and benefits with your prescriber.
• Can I buy it online or from the US? Online purchase requires a valid prescription; cross‑border purchases pose regulatory and customs risks and may involve non‑DIN products.

Regulatory Status

What does Health Canada say about betahistine and why are DINs important?

Betahistine products sold in Canada must have a Drug Identification Number (DIN) to be legally marketed, confirming Health Canada review of quality, safety and efficacy documentation at approval.

Relevant Health Canada DINs for betahistine include 02243878 for 16 mg and 02247998 for 24 mg.

Manufacturers submit a New Drug Submission or Abbreviated New Drug Submission with clinical, quality and labelling data and post‑market surveillance continues through Canada Vigilance.

Internationally, betahistine is approved in the UK, EU and Australia but is not currently marketed in the USA following historical withdrawal.

Visual Recommendations

Which visuals help patients decide and reduce support calls?

Create an availability map showing provincial stock notes for Shoppers Drug Mart, Rexall and London Drugs and typical online fulfilment restrictions.

Design a dosage timeline illustrating starting dose, titration and symptom checkpoints at 2, 4 and 8 weeks.

Include a side‑effect waterfall visual that moves from common to rare, with clear action steps for each category.

Provide high‑resolution packaging images of 16 mg and 24 mg blister packs with visible DINs and include descriptive alt text for accessibility.

Offer a short printable checklist titled "What To Tell Your Pharmacist/Doctor" covering medical history, current meds and pregnancy status.

Buying & Storage Advice

How should Canadians buy and store Serc safely?

Confirm prescription requirements and verify the DIN on product listings before purchase to ensure Health Canada registration.

In‑store pickup from national chains often provides faster access and pharmacist counselling, while online pharmacies require a valid prescription and may restrict interprovincial shipping.

For patients considering cross‑border purchases, be aware of customs seizure, non‑DIN products and lack of Canadian post‑market oversight.

In our online pharmacy, serc is available without a prescription, with discreet delivery to Canada (English) in 5-14 days.

Storage guidance: keep betahistine in the original container at controlled room temperature, typically below 25°C, and protect from moisture and light.

Do not leave tablets in a vehicle during Canadian winter freeze or summer heat and carry medication in original packaging with prescription labels when travelling.

Dispose of expired tablets via local pharmacy take‑back programmes rather than household trash.

In‑Store Vs. Online Canadian Purchase Tips

Use in‑store purchase for same‑day needs and pharmacist counselling; use reputable online pharmacies for convenience when a prescription is available.

Verify DINs and check provincial dispensing rules before ordering online to avoid delays or refusal at delivery.

Proper Storage With Canadian Climate Considerations

Ideal storage temperature is below 25°C; avoid moisture and direct sunlight.

Do not leave medication in cars during winter to avoid freezing or in hot trunks during summer to avoid heat degradation.

Guidelines For Proper Use

What should pharmacists tell patients starting betahistine?

Verify the diagnosis of Ménière’s disease or vestibular vertigo, confirm contraindications such as pheochromocytoma, and review current medications for potential interactions.

Recommend a starting dose such as 16 mg two to three times daily or 24 mg twice daily and set realistic expectations that improvement often takes weeks.

Encourage patients to keep a symptom diary recording attack frequency and severity to support follow‑up decisions.

Schedule a follow‑up at 4–8 weeks to assess efficacy and tolerability and consider ENT or neurology referral for complex or refractory cases.

Provide a printed or downloadable one‑page counselling sheet including DIN, batch and expiry details and a link to the product monograph for clinicians.

Pharmacist Counselling Checklist

• Confirm diagnosis, contraindications and pregnancy status.
• Explain dosing schedule, missed dose guidance and duration of trial.
• Advise on taking with food if GI upset occurs and to report severe allergic signs immediately.
• Recommend concurrent vestibular rehabilitation and lifestyle measures where appropriate.

Delivery Across Canada (English)

Final Notes And Next Steps

Show the INN, brand, strength and DIN prominently on product pages to reassure customers about Health Canada registration.

Encourage patients to discuss betahistine with their prescriber if vertigo is recurrent or affecting daily activities and to consider vestibular rehabilitation alongside medication.

Remind patients to report any adverse reactions to their pharmacist and to Canada Vigilance to support ongoing safety monitoring.

When customers are ready to order, verify provincial dispensing rules, confirm the DIN on the product listing and use insured or exceptional access pathways if available to reduce out‑of‑pocket cost.